House Dietary Supplement Listing Bill Sparks Industry Debate on Transparency and Regulatory Burden

A newly introduced House bill¹ aimed at establishing a mandatory dietary supplement product listing system is reigniting a longstanding debate over transparency, regulatory oversight, and industry burden.

Rep. Maxine Dexter, MD (D-OR), recently introduced legislation that would require dietary supplement manufacturers to submit product information, including labels and ingredient details, to the FDA. Framing the legislation as a public health and transparency measure, Dexter emphasized the widespread use of supplements and the need for improved regulatory visibility.

“More than three-quarters of Americans take dietary supplements. As a physician, I’ve seen countless patients assume these products are vetted for safety,” Dexter explained in a statement.² “Unfortunately, our regulatory bodies don’t have access to the most basic information about these products. My common sense legislation brings transparency to consumers and regulators alike to keep our communities safe.”

The proposal reflects growing congressional interest in modernizing oversight of a marketplace that has expanded significantly since passage of the Dietary Supplement Health and Education Act of 1994 (DSHEA), which modified the Federal Food, Drug, and Cosmetic Act to formally define dietary supplements as a special category of food, rather than drugs.³

It also isn’t the first time a piece of legislation relating to the topic was proposed. Earlier this year, US Senate Majority Whip Dick Durbin (D-IL) re-introduced a version of the bill to the US Senate, after initially presenting it to his fellow constituents in 2022.

What Problem Is the Dietary Supplement Listing Bill Trying to Solve?

The proposed legislation is designed to address what supporters describe as a lack of comprehensive visibility into the supplement marketplace. While DSHEA established the modern regulatory framework, it does not require companies to register products with FDA prior to marketing, leaving gaps in the agency’s ability to track the full scope of products available.

Advocates argue that a centralized database would improve enforcement efficiency, help identify adulterated or misbranded products, and increase consumer confidence.

Why Does CRN Support Mandatory Product Listing?

The Council for Responsible Nutrition (CRN), one of the trade associations representing the dietary supplement and functional food industry, has strongly endorsed the House bill, framing it as a practical step toward greater accountability.

“CRN welcomes Rep. Maxine Dexter’s (D-OR) introduction of a House version of the Dietary Supplement Listing Act, which adds growing momentum to the calls for radical transparency in the dietary supplement industry… A federal dietary supplement registry is a commonsense solution designed to shine sunlight into the marketplace, enabling FDA to more efficiently identify problems and for retailers to better curate their offerings with quality products,” stated Steve Mister, the association’s president and CEO.⁴

CRN maintains that FDA has acknowledged limitations in its current visibility and that a standardized registry would close that gap without fundamentally altering DSHEA or restricting consumer access.

Why Is NPA Opposing the Bill?

In contrast, the Natural Products Association (NPA) has issued a strong rebuke⁵ of the legislation, arguing that it is unnecessary and potentially harmful.

According to the NPA, the bill “would require manufacturers to register their products with FDA, despite the absence of any credible evidence that FDA lacks the authority or information today to effectively oversee the marketplace and protect public health.”

The organization contends that FDA already has tools to monitor safety and take enforcement action, and that the proposal is based on a “false narrative” about regulatory gaps.

NPA also warned that creating a centralized database could expose companies to increased legal risk and administrative burden. The group stated the system could become a “litigation trap,” potentially enabling opportunistic lawsuits based on technical interpretations of labeling or compliance requirements.

Daniel Fabricant, NPA’s president and CEO, added that the bill could divert resources away from innovation and product development, ultimately slowing progress in the category.⁵

These concerns align with broader NPA arguments, specifically around the idea that mandatory listing adds bureaucracy without effectively addressing bad actors or improving enforcement outcomes.

Where Does AHPA Stand on Product Listing?

The American Herbal Products Association (AHPA) has taken a more nuanced position, supporting transparency in principle while raising concerns about specific provisions in the House bill.

As noted by Graham Rigby,⁶ the association’s president and CEO, “AHPA remains committed to fostering a transparent, innovative dietary supplement industry that prioritizes public health. We welcome additional Congressional interest in modernizing the regulatory framework for our industry; however, while we do not oppose the concept of product listing in principle, we cannot support a proposal that would require companies to add a listing number to product labels without significant changes. We will continue our direct engagement with Congress to develop meaningful, common-sense reforms that increase accountability and meet the needs of today's dietary supplement marketplace and consumers.”

Rigby’s thoughts reflect an interest in modernization, combined with caution around implementation details that could create unintended burdens.

What Happens Next?

The introduction of the House bill adds momentum to parallel efforts in the Senate, signaling growing bipartisan attention to supplement regulation. However, significant differences remain among stakeholders regarding the necessity, scope, and structure of a mandatory listing system.

As debate continues, the outcome will likely hinge on whether lawmakers can reconcile competing priorities, such as improving transparency and enforcement while preserving innovation, minimizing regulatory burden, and maintaining consumer access.

References

1. Dexter M. Dietary supplement listing act of 2026. US House of Representatives. Published April 3, 2026. Accessed April 23, 2026. https://dexter.house.gov/sites/evo-subsites/dexter.house.gov/files/evo-media-document/dietary-supplement-listing_02_xml.pdf

2. Dexter M. Dexter introduces bill to bring transparency to multi-billion dollar supplement industry. US. House of Representatives. April 20, 2026. Accessed April 23, 2026. https://dexter.house.gov/media/press-releases/dexter-introduces-bill-bring-transparency-multi-billion-dollar-supplement

3. US Food and Drug Administration. Dietary supplements. Accessed April 23, 2026. https://www.fda.gov/food/dietary-supplements

4. Council for Responsible Nutrition. New supplement registry legislation signals bicameral interest in making the dietary supplement market more transparent. April 23, 2026. Accessed April 23, 2026. https://www.crnusa.org/newsroom/new-supplement-registry-legislation-signals-bicameral-interest-making-dietary-supplement

5. Natural Products Association. Natural Products Association slams introduction of Dietary Supplement Listing Act. April 21, 2026. Accessed April 23, 2026. https://www.npanational.org/news/natural-products-association-slams-introduction-of-dietary-supplement-listing-act/#:~:text=Washington%2C%20D.C.%20%E2%80%93%20The%20Natural%20Products,is%20confronting%20an%20accelerating%20wave

6. American Herbal Products Association. Dietary Supplement Listing Act. April 23, 2026. Accessed April 23, 2026. Statement provided via email.